Table 1 Studies with control group included in meta-analysis – the table taken from the study by Wolinski et al. [4], modified. Asterisk (*) - persons with non-functioning or Prl secreting adenomas.
Studies with control group | Acromegalic patients | Cases of thyroid carcinoma in group of acromegalic patients | Control group | Cases of thyroid carcinoma in control group | Odds ratio |
|---|---|---|---|---|---|
dos Santos et al., Pituitary 2013;16:109-114 | 124 | 9 (7.25%) | 263 (not specified) | 2 (0.76%) | 9.5 (2.2-48.0) |
Herrmann et al., Clin Endocrinol Diabet. 2004;112:225–230; retrospective | 73 | 4 (5.5%) | 199 (healthy volunteers) | 0 | 25.8 (1.4-486.0) |
Gasperi et al., J Endocrinol Invest. 2002;25:240-245 | 258 | 3 (1.16%) | 150* | 1 (0.66%) | 1.7 (0.2-16.9) |
Popovic et al. Clin Endocrinol (Oxf) 1998;49: 441–445; retrospective | 220 | 3 (1.36%) | 248* | 0 | 8.0 (0.4-155.7) |
Barzilay et al., Arch Intern Med. 1991;151:1629–1632; retrospective | 87 | 2 (2.3%) | 198* | 0 | 11.6 (0.6-244.4) |
Total | 7.9 (2.8-22.0) |